Hikal Ltd.

NSE: HIKAL | BSE: 524735 | ISIN: INE475B01022 | Industry: Pharmaceuticals
| Expensive Star

logo
Hikal Ltd.
12 Aug 2021
409.20
-3.86%
BP Wealth
Hikal posted revenue of INR 4,568mn with 29.5% YoY growth which was slightly below our estimate of INR 4,627mn on account of lower production days due to the unavailability of oxygen for industrial use. On segmental performance: The crop protection segment grew by 31% (YoY) to INR 1,827mn on the back of Increased sales volume of existing as well as new products. Pharmaceutical segment revenue surged by 28% to INR 2,741mn based on increased volumes of existing API Generics and CDMO products. EBITDA margin improved by 607 bps to 21%, (was 277bps above our estimate) supported by a favourable product mix. EBIT margin of the Crop protection segment improved by 532bps (YoY) with 40% (vs 43.6% in Q1FY21) contribution to overall EBIT. The pharmaceutical...
Hikal Ltd. has an average target of 420.00 from 1 broker.
More from Hikal Ltd.
Recommended